The world has been fixated for months on novel-coronavirus PCR testing, contact tracing and vaccination.
Meanwhile, another major part of the Covid biomedical complex has received far less attention: the use of antibodies for detecting, diagnosing and treating infection with the novel coronavirus.
Hundreds of antibodies have been approved for these purposes since January 2020. And hundreds more are poised to start being marketed soon.
This is part of the biomedical gold rush: by last summer already, antibodies were on track to become the most lucrative medical product, with global revenue projected to reach nearly half a trillion dollars by 2024. Profit margins in the range of 67% aren’t uncommon.
Pharma giants such as AstraZeneca, Novartis, GlaxoSmithKline and Eli Lilly are among the companies grabbing the largest chunks of the novel-coronavirus-antibody market. And some of the most muscular government agencies, including Anthony Fauci’s US National Institute of Allergy and Infectious Diseases and the US’s Defense Advanced Research Projects Agency, are part of the action... (more...)
The Antibody Deception from Rosemary Frei on Vimeo.
No comments:
Post a Comment